SAN DIEGO  In almost hushed tones to reporters gathered in a corner room of the San Diego Convention Center at BIO 2014, Bionomics Ltd. CEO Deborah Rathjen unveiled late Monday the firm's second deal in less than a year with Merck & Co. Inc., this time a potential $526 million arrangement focused on a preclinical therapy targeting Alzheimer's disease (AD).